Instead of optimizing ADC linker-payload technology like many competitors, Ona Therapeutics licenses best-in-class components. Their unique edge comes from identifying novel tumor antigens by analyzing sequential patient biopsies from Spanish hospitals, a proprietary data source that provides a durable competitive advantage.
Ona Therapeutics' CEO rejected an unlimited holiday policy after observing it often leads to employees taking almost no vacation, which is counterproductive to performance. She instead focuses on a flexible work schedule while actively encouraging her team to take their designated holidays to properly rest and recharge.
The name "Ona Therapeutics" holds a deep personal meaning for founder Valerie Vanhooren: it was the name she had chosen for a daughter she never had. This backstory transforms the company's identity into her "daughter," creating an emotionally resonant and memorable brand narrative that goes beyond typical corporate naming conventions.
Ona Therapeutics' CEO stresses that honesty, even admitting a lack of data, is crucial when fundraising. Investors are trained to detect dishonesty. Acknowledging what you don't know and explaining your plan to find out is more effective and builds more credibility than bluffing your way through a tough question.
Ona Therapeutics maintains a small team by following a simple rule: outsource functions that external experts can do better (like CROs and manufacturing) at a reasonable price. This allows them to focus all internal resources on their core, specialized competency of designing novel molecules and advancing their pipeline.
While the US leads in capital access, Ona Therapeutics' CEO highlights a key European advantage: the ability to hire top-tier scientific talent at a significantly lower cost. A scientist in Barcelona, for instance, costs much less than one in Boston but can be equally skilled and satisfied with their compensation.